Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

American Journal of Kidney Diseases

Volumn 73, Issue 3, 2019, Pages 309-315

  Mc Causland, Finnian R ^a,b   Claggett, Brian ^a,b   Burdmann, Emmanuel A ^c   Chertow, Glenn M ^d   Cooper, Mark E ^e   Eckardt, Kai Uwe ^f   Ivanovich, Peter ^g   Levey, Andrew S ^h   Lewis, Eldrin F ^a,b   McGill, Janet B ⁱ   McMurray, John J V ^j   Parfrey, Patrick ^k   Parving, Hans Henrik ^l   Remuzzi, Giuseppe ^m,n,o   Singh, Ajay K ^a,b   Solomon, Scott D ^a,b   Toto, Robert D ^p   Pfeffer, Marc A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g NORTHWESTERN UNIVERSITY   (United States)

^h TUFTS MEDICAL CENTER   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

^k MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^l University of Copenhagen   (Denmark)

^m MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

ⁿ Unit of Nephrology and Dialysis   (Italy)

^o UNIVERSITY OF MILAN   (Italy)

^p UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

Anemia; cardiovascular disease; chronic kidney disease (CKD); darbepoetin; death; dialysis; dialysis initiation; erythropoiesis stimulating agent (ESA); hemoglobin (Hb); incident dialysis; stroke; transition to dialysis; type 2 diabetes mellitus (T2DM)

Indexed keywords

HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ADULT; AGED; ALL CAUSE MORTALITY; ANEMIA; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; CARDIOVASCULAR DISEASE; COMPLICATION; HEMODIALYSIS; PROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANEMIA; CARDIOVASCULAR DISEASES; DARBEPOETIN ALFA; DOUBLE-BLIND METHOD; FEMALE; HEMATINICS; HUMANS; MALE; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 85058797340     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2018.10.006     Document Type: Article

References (28)

1. Saran, R., Robinson, B., Abbott, K.C., et al. US Renal Data System 2016 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis 69:3 suppl 1 (2017), A7–A8.
2. Robinson, B.M., Zhang, J., Morgenstern, H., et al. Worldwide, mortality risk is high soon after initiation of hemodialysis. Kidney Int 85:1 (2014), 158–165.
3. Eckardt, K.-U., Gillespie, I.A., Kronenberg, F., et al. High cardiovascular event rates occur within the first weeks of starting hemodialysis. Kidney Int 88:5 (2015), 1117–1125.
4. El-Achkar, T.M., Ohmit, S.E., McCullough, P.A., et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: the Kidney Early Evaluation Program. Kidney Int 67:4 (2005), 1483–1488.
5. Thomas, M.C., MacIsaac, R.J., Tsalamandris, C., Power, D., Jerums, G., Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care 26:4 (2003), 1164–1169.
6. Vlagopoulos, P.T., Tighiouart, H., Weiner, D.E., et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 16:11 (2005), 3403–3410.
7. Mohanram, A., Zhang, Z., Shahinfar, S., Keane, W.F., Brenner, B.M., Toto, R.D., Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 66:3 (2004), 1131–1138.
8. Singh, A.K., Szczech, L., Tang, K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:20 (2006), 2085–2098.
9. Drüeke, T.B., Locatelli, F., Clyne, N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:20 (2006), 2071–2084.
10. Pfeffer, M.A., Burdmann, E.A., Chen, C.-Y., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:21 (2009), 2019–2032.
11. Parfrey, P.S., Foley, R.N., Wittreich, B.H., Sullivan, D.J., Zagari, M.J., Frei, D., Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16:7 (2005), 2180–2189.
12. Besarab, A., Bolton, W.K., Browne, J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:9 (1998), 584–590.
13. Coyne, D.W., The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 82:2 (2012), 235–241.
14. Pfeffer, M.A., Burdmann, E.A., Chen, C.-Y., et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis 54:1 (2009), 59–69.
15. Mc Causland, F.R., Claggett, B., Pfeffer, M.A., et al. Change in hemoglobin trajectory and darbepoetin dose approaching end-stage renal disease: data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. Am J Nephrol 46:6 (2017), 488–497.
16. Austin, P.C., Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:25 (2009), 3083–3107.
17. Foley, R.N., Parfrey, P.S., Harnett, J.D., Kent, G.M., Murray, D.C., Barre, P.E., The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28:1 (1996), 53–61.
18. Xia, H., Ebben, J., Ma, J.Z., Collins, A.J., Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10:6 (1999), 1309–1316.
19. Locatelli, F., Pisoni, R.L., Combe, C., et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19:1 (2004), 121–132.
20. Ma, J.Z., Ebben, J., Xia, H., Collins, A.J., Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:3 (1999), 610–619.
21. Ofsthun, N., Labrecque, J., Lacson, E., Keen, M., Lazarus, J.M., The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 63:5 (2003), 1908–1914.
22. Messana, J.M., Chuang, C.-C., Turenne, M., et al. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model. Am J Kidney Dis 53:3 (2009), 503–512.
23. Regidor, D.L., Kopple, J.D., Kovesdy, C.P., et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17:4 (2006), 1181–1191.
24. Brookhart, M.A., Schneeweiss, S., Avorn, J., Bradbury, B.D., Liu, J., Winkelmayer, W.C., Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 303:9 (2010), 857–864.
25. Levin, A., Djurdjev, O., Duncan, J., Rosenbaum, D., Werb, R., Haemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long-term outcomes. Nephrol Dial Transplant 21:2 (2006), 370–377.
26. Skali, H., Parving, H.-H., Parfrey, P.S., et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa: the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) experience. Circulation 124:25 (2011), 2903–2908.
27. Swedberg, K., Young, J.B., Anand, I.S., et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368:13 (2013), 1210–1219.
28. Bello, N.A., Lewis, E.F., Desai, A.S., et al. Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. Eur J Heart Fail 17:11 (2015), 1201–1207.